The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...

BURLINGTON, Mass. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company focused on molecular imaging diagnostics, today announced results from an investigational clinical trial ...

In patients with PSA levels ≤ 1.78 ng/mL, 15 of 25 had a positive scan, with 11 confirmed as positive by histology; 71 of 74 patients with PSA levels > 1.78 ng/mL had a positive scan, of which 58 were ...

VICTORVILLE — A new prostate cancer scan that is extending the lives of patients is now available in the High Desert. Axumin is a recently FDA-approved imaging agent that detects recurrent cancer ...

A new effective PET/CT scan for prostate cancer patients can detect the location and extent of cancer that has recurred after initial treatment. Prostate PET/CT scans can detect cancer earlier than ...

Please provide your email address to receive an email when new articles are posted on . The FDA today approved Axumin, an injectable radioactive diagnostic agent used to detect recurrent prostate ...

The US Food and Drug Administration (FDA) approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected ...

Comments on this technology were invited from clinical experts working in the field. The comments received are individual opinions and do not represent NICE's view. Two out of 6 specialist ...

Axumin PET has received orphan drug designations in glioma from the FDA and the European Medicines Agency. (Wikimedia Commons) () A phase 3 study from molecular imaging firm Blue Earth Diagnostics ...

Patients must be routinely checked for prostate cancer recurrence after prostate cancer surgery. Statistically, prostate cancer has a higher chance of recurrence. Patients should undergo a routine ...